|
Link |
|
29 juni, 2026
Biostock: SynAct Pharma: ’Best BIO ever"
|
|
|
18 juni, 2026
Edison: SynAct Pharma — Secondary endpoints reshape the debate
|
|
|
17 juni, 2026
Biostock: SynAct's CEO comments on the RA study
|
|
|
16 juni, 2026
Medwatch interview: From Clinical Data to Deal Talks: SynAct Targets a Major Partnership (DK)
|
|
|
16 juni, 2026
Biostock: SynAct Comments on the ADVANCE Phase IIb Results and next steps
|
|
|
15 juni, 2026
Edison: CBO Mads Bjerregaard on ADVANCE results, future development plans and upcoming milestones for SynAct Pharma
|
|
|
11 juni, 2026
Edison : SynAct Pharma — Key upcoming readouts to shape outlook
|
|
|
11 juni, 2026
Interview with CBO Mads Bjerregaard "VILL ÅTERSKAPA EXPANDSTUDIENS RESULTAT" (SV)
|
|
|
25 maj, 2026
CBO Mads Bjerregaard presents SynAct Pharma at Global Forum 2026
|
|
|
27 april, 2026
Biostock: What good data looks like: SynAct Pharma ahead of its ADVANCE readout
|
|
|
22 april, 2026
Edison Group: SynAct Pharma - The sharp take: insights from the capital markets day
|
|
|
18 mars, 2026
Biostock: SynAct Pharma lays out dual strategy for resolution therapy at capital markets day
|
|
|
17 mars, 2026
REDEYE: SynAct Pharma (Interview): Paving the Way for Clinical Validation
|
|
|
3 mars, 2026
REDEYE: SynAct Pharma - Interview about the directed share issue
|
|
|
3 mars, 2026
Edison Group: SynAct Pharma — Multiple shots on goal in 2026 for resomelagon
|
|
|
3 mars, 2026
Biostock: SynAct Pharma secures 51,9 million SEK to strengthen clinical runway
|
|
|
19 februari, 2026
Biostock: SynAct Pharma on dual studies, partner interest and commercial potential
|
|
|
3 februari, 2026
REDEYE: SynAct Pharma (Interview): Redeye speaks with CSO Thomas Jonassen
|
|
|
2 januari, 2026
Biostock: SynAct Pharma kicks off 2026 ahead of ADVANCE results
|
|
|
22 december, 2025
Biostock: SynAct Pharma: ”2026 is going to be a busy year”
|
|
|
20 november, 2025
REDEYE: SynAct Pharma (interview): Redeye speaks with CBO Mads Bjerregaard
|
|
|
10 oktober, 2025
Biostock: SynAct Pharma’s CBO: “We are pioneering the future of inflammation care”
|
|
|
13 januari, 2025
SynAct Pharmas emission övertecknades
|
|
|
28 november, 2024
Biostock: Nya investerare och storägare backar SynActs kapitalanskaffning – vd kommenterar
|
|
|
20 november, 2024
Affärsvärlden: Synact gör fyra emissioner – Krys medgrundare går in
|
|
|
4 juli, 2024
Biostock: SynAct Pharma moves forward with filing process
|
|
|
2 maj, 2024
BioStock: SynAct Pharma’s CEO provides an update
|
|
|
2 april, 2024
BioStock – Synact focuses on pushing forward rheumatoid arthritis project
|
|
|
22 mars, 2024
BioStock: Interview with SynAct’s CEO and CSO
|
|
|
20 mars, 2024
Direkt: Newly elected CEO & Chairman interviewed
|
|
|
19 september, 2023
BioStock: Positive subgroup data in SynAct Pharmas’s EXPAND study
|
|
|
7 september, 2023
BioStock: SynAct Pharma’s CEO comments on EXPAND data
|
|
|
4 september, 2023
Direkt: Comment on the EXPAND top line data presented today
|
|
|
21 juli, 2023
BioStock: SynAct Pharma’s CEO comments on the recent progress
|
|
|
17 maj, 2023
BioStock: Highlights from SynAct Pharma’s Capital Markets Day
|
|
|
April 3, 2023
Direkt: Changes to management
|
|
|
March 1, 2023
Company presentation
|
|
|
24 februari, 2023
BioStock: Progress for SynAct Pharma in 2022 – more milestones ahead
|
|
|
20 december, 2022
BioStock: Interview regarding TXP
|
|
|
12 december, 2022
Presentation related to TXP Acquisition and Directed Share Issue
|
|
|
4 november, 2022
BioStock: Interview with CSO Thomas Jonassen
|
|
|
10 oktober, 2022
BioStock: SynAct submits IND and recruits first patient in phase 2b.
|
|
|
20 september, 2022
SynAct Pharma wins two awards at GHP 2022
|
|
|
9 juni, 2022
Presentation at BioStock Life Science Spring Summit
|
|
|
1 juni, 2022
Presentation at Life Science Investor Konference, June 1, 2022 – Copenhagen
|
|
|
6 april, 2022
BioStock: SynAct Pharma’s CEO on the rights issue and partnering discussions
|
|
|
28 mars, 2022
Presentation regarding the Rights Issue 2022
|
|
|
14 februari, 2022
BioStock: SynAct Pharma well positioned for an eventful 2022
|
|
|
10 december, 2021
MedWatch: Synact Pharma vil intensivere partner-drøftelser
|
|
|
3 december, 2021
BioStock Studio: SynAct Pharma comments on the promising study results in RA
|
|
|
30 november, 2021
Scrip: SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II
|
|
|
30 november, 2021
SynAct Pharma’s AP1189 meets primary endpoint – Nordic Life Science – the leading Nordic life science news service
|
|
|
11 november, 2021
BioStock: SynAct Pharma’s CSO and CMO comment on clinical development
|
|
|
28 juli, 2021
Nordic Life Science News: SynAct Pharma announces positive additional trial data
|
|
|
30 juni, 2021
DagensPS: Lungfunktion vid Covid-19 förbättras med svensk läkemedelskandidat
|
|
|
17 juni, 2021
Healthcare Direkt v. 24 l Synact Pharma om kommande fas 2-resultat
|
|
|
5 februari, 2021
Finwire – En tydlig utvecklingsplan för AP1189 stärker förhandlingspositionen
|
|
|
11 november, 2020
SynAct Pharma mentioned in the Rheumatoid Arthritis (RA) – Pipeline Insight, 2020
|
|
|
23 september, 2020
DI (Nyhetsbyrån Direkt): Synact Pharma startar fas 2-studie med covid-patienter
|
|
|
22 september, 2020
BIOSTOCK: SynAct Pharma ser potential inom flera virussjukdomar
|
|
|
22 september, 2020
BIOSTOCK: SynAct Pharma sees potential in several viral diseases
|
|
|
3 juli, 2020
Cision Promoted: Emission teckningsoptioner ska driva två projekt genom fas II
|
|
|
30 juni, 2020
Aktiespararna: Intensiv höst med sikte på utlicensiering i horisonten
|
|
|
2 juni, 2020
BIOSTOCK: SynAct närmar sig studiestart efter myndighetsgodkännande
|
|
|
12 maj, 2020
Redeye: Interview with CEO Jeppe Øvlesen and CSO Thomas Jonassen (video call)
|
|
|
6 maj, 2020
BIOSTOCK: SynAct comments on positive Phase II data
|
|
|
2 april, 2020
BIOSTOCK: SynAct Pharma om Covid-19-satsningen (in Swedish)
|
|
|
2 april, 2020
BIOSTOCK: Synact Pharma on expansion into Covid-19
|
|
|
1 april, 2020
Medwatch: Synact rekrutterer fortsat til forsøg trods pandemi (in Danish)
|
|
|
1 april, 2020
Synact Pharma in spotlightanalysen (in Swedish)
|
|
|
31 mars, 2020
Dagens Industri: Spotlight-bolag planerar preparattester på coronapatienter (in Swedish)
|
|
|
31 mars, 2020
Medwatch: Synact Pharma vil teste hovedkandidat som tillægsbehandling til coronasyge patienter (in Danish)
|
|
|
31 mars, 2020
Life Science Sweden: Vill dämpa lunginflammationen vid covid-19 (in Swedish)
|
|
|
6 december, 2019
Medwatch: Synact Pharma kommer i mål med aktieemission – overtegnet med 295 pct (in Danish)
|
|
|
12 november, 2019
Medwatch: Synact får grønt lys til forsøg i Sverige (in Danish)
|
|
|
21 oktober, 2019
Medwatch: Biotekselskab vil starte nyt forsøg med hovedaktiv og udsteder aktier for millioner (in Danish)
|
|
|
28 juni, 2019
Medwatch: Biotekchef lander ny bestyrelsespost efter hjemtur til Danmark (in Danish)
|
|
|
1 april, 2019
Medwatch: Synact er klar til fase 2 med gigthåb: “En stor milepæl for selskabet” (in Danish)
|
|
|
1 april, 2019
Medwatch: Synact ready for phase II with arthritis candidate: “An important milestone for the company”
|
|
|
11 februari, 2019
Medwatch: Synact skal rejse 14 mio kr til nyt forsøg med hovedkandidat (in Danish)
|
|
|
21 augusti, 2018
Medwatch: Synact Pharmas hovedkandidat viser lovende takter mod sjælden nyresygdom (in Danish)
|
|
|
12 maj, 2018
Medwatch: Synact Pharma fordobler svensk kapitalrejsning (in Danish)
|
|
